Brought to you by 
NightstaRx closes $45mm Series C round
30 Jun 2017
Executive Summary
NightstaRx Ltd. (gene therapies for inherited retinal diseases) raised $45mm in its Series C financing to first-time backers Wellington Management Company and Redmile Group, which were joined by returning shareholders Syncona and New Enterprise Associates. The company will use the funds for pipeline development, including a Phase III trial of lead compound NSRREP1 for choroideremia, a Phase I/II study of NSRRPGR for X-linked retinitis pigmentosa, and a Phase I/II trial of a candidate for an inherited form of macular dystrophy.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NightstaRx closes $45mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice